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Aging is the greatest risk factor of developing age-
related macular degeneration (AMD) — the most 
common reason of irreversible vision loss and blindness 
in the elderly [1,2]. The late stage of the disease is 
characterized by choroidal neovascularizations (CNV) 
which protrude through the basal membrane (Bruch’s 
membrane)  of  retinal  pigment  epithelium  (RPE)  and  
 
into the neuroretina leading to visual symptoms such as 
metamorphopsia, blurred vision, and scotoma [3]. This 
stage of the disease is called neovascular AMD and is 
associated with retinal aging and dysfunction [5]. 
Alterations of the innate and adaptive immune system in 
the elderly play a key role in retinal immune homeo-
stasis, vascular endothelial growth factor (VEGF) 
expression upon injury, and promotion of angiogenesis 
[6-11]. Polypoidal choroidal vasculopathy (PCV) is an 
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Polypoidal  choroidal  vasculopathy  (PCV)  and  neovascular  age‐related  macular  degeneration  (AMD)  are
prevalent  age‐related  diseases  characterized  by  exudative  changes  in  the  macula.  Although  they  share
anatomical and clinical  similarities,  they are also distinctly characterized by  their own  features, e.g. vascular
abnormalities  in  PCV  and  drusen‐mediated  progression  in  neovascular  AMD.  PCV  remains  etiologically
uncharacterized,  and  ongoing  discussion  is whether  PCV  and  neovascular  AMD  share  the  same  etiology  or
constitute  two  substantially different diseases.  In  this  study, we  investigated T‐cell differentiation and aging
profile  in  human  patients  with  PCV,  patients  with  neovascular  AMD,  and  age‐matched  healthy  control
individuals.  Fresh  venous  blood  was  prepared  for  flow  cytometry  to  investigate  CD4+  and  CD8+  T‐cell
differentiation  (naïve,  central  memory,  effector  memory,  effector  memory  CD45ra+),  loss  of  differentiation
markers CD27 and CD28, and expression of aging marker CD56. Patients with PCV were similar to the healthy
controls  in  all  aspects.  In  patients  with  neovascular  AMD  we  found  significantly  accelerated  T‐cell
differentiation  (more CD28‐CD27‐  cells)  and  aging  (more CD56+  cells)  in  the  CD8+  T‐cell  compartment.  These
findings suggest that PCV and neovascular AMD are etiologically different in terms of T cell immunity, and that
neovascular AMD is associated with T‐cell immunosenescence. 
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important differential diagnosis to neovascular AMD 
with shared visual symptoms but different anatomical 
and clinical characteristics [12,13]. PCV is charac-
terized by the acquired polypoidal deformations at the 
terminal of CNVs [12,13]. These polyps protrude into 
the sub-RPE space, often with accompanying branching 
vascular networks [12,13]. Differences with 
neovascular AMD may seem subtle, but diagnosing 
PCV have important clinical implications: neovascular 
AMD is managed solely by regular intravitreal 
injections with VEGF inhibitors, whereas PCV may 
benefit from a combination of VEGF inhibitors to limit 
exudates and photodynamic therapy for polyp 
regression [12-16]. PCV is diagnosed in ~6-10 % of 
Caucasians and ~50 % of Asians with presumed 
neovascular AMD who undergo detailed retinal 
diagnosis using indocyanine green retinal angiography 
[12,13,17]. Hence, PCV is a relatively common disease 
with distinct clinical and anatomical differences [18], 
but very little is known regarding its etiology. One 
important question remains unanswered: is PCV a 
different clinical manifestation of a disease that etio-
logically is the same as neovascular AMD, or should we 
consider PCV a disease that is distinguished by its own 
etiology? 
 
Comparative etiological studies of PCV and 
neovascular AMD are sparse. Tong et al. found that 
intraocular levels of VEGF is increased in eyes with 
PCV, but at a lower level than in eyes with neovascular 
AMD [19]. Zeng et al. investigated extracellular tissue 
homeostasis and found increased level of serum matrix 
metalloproteinases 2 and 9 in patients with PCV 
compared to patients with neovascular AMD and 
healthy controls [20]. Genetic studies suggest both 
similarities and differences and at present generally 
neither confirm nor reject a possible association of PCV 
with alterations in the immune system [21].  
 
Immune dysfunction plays a key role in the etiology of 
neovascular AMD [22]. Important findings include 
complement dysfunction [23,24], altered innate immune 
system [6-8,22], and changes in the adaptive immune 
system [6,9-11]. The latter is an emerging field of 
research with interesting findings so far suggesting that 
the adaptive immune system may be involved in the 
etiology of neovascular AMD. We previously found 
that patients with neovascular AMD have a lower 
proportion of T helper 1 cells as well as dysfunctions in 
the expression of T-cell chemokine receptors [9,10]. 
Murine models of experimental CNV find systemic 
activation of T helper cells [25]. In vitro studies of 
activated T-cells and their cytokines have demonstrated 
two important mediators in the etiology by modulating 
the protein expression and secretion in retinal pigment 
epithelium (RPE) cells: increased expression and 
secretion of chemokines [26] and increased expression 
and secretion of complement proteins [27] that 
constitute a main part of retinal drusen formation — the 
sine qua non of AMD.  
 
Considering that PCV and neovascular AMD are only 
seen in the aged, we turned our attention to immuno-
senescence — age-related changes of the immune 
system [28]. The thymic output of T-cells peaks at 
puberty and declines gradually afterwards, and the 
declined running supply of naïve T-cells consequently 
results in a higher ratio of more differentiated T-cells 
[28]. Differentiated and activated T-cells become 
central memory or effector memory T-cells with 
different set of surface markers and function [29]. T-cell 
differentiation and proliferation also leads to gradual 
loss of CD27 and CD28 expression: CD4+ T-cells lose 
CD27 first and CD28 later; whereas the opposite is the 
case for CD8+ T-cells, which lose CD28 first, and CD27 
later [29]. Details on T-cell differentiation profile are 
not previously investigated in patients with PCV or 
neovascular AMD. We previously investigated CD56 
expression on CD28- T-cells and found significant 
differences between patients with AMD and healthy 
controls [11]. CD56 is a surface marker of natural killer 
cells, but is also expressed broadly among leukocyte 
subsets [30]. In T-cells, CD56 expression is linked to an 
increased cytolytic activity [30]. However, from 
immunosenescence point-of-view, CD56 is interesting 
since it is one of the best described markers of T-cell 
aging [31-33]. CD56 expression has not been studied in 
patients with PCV and the role of T-cells in PCV 
remains unexplored. 
 
Our aim with this study was to investigate T-cell aging 
and differentiation by mapping the differentiation 
profile and investigating the proportion of CD56+ T-
cells in different differentiation subsets in patients with 
PCV and compare the results to that of patients with 




We recruited 24 patients with PCV, 50 patients with 
neovascular AMD, and 26 healthy controls. We post-
hoc excluded five patients with neovascular AMD and 
two healthy controls because we suspected an ongoing 
acute immune response due to elevated plasma C-
reactive protein levels (> 15 mg/L). Therefore, our 
analyses are based on 24 patients with PCV, 45 patients 
with neovascular AMD, and 24 healthy controls. 
Participant characteristics (demographics, co-morbidi-
ties, and lifestyle factors) did not differ significantly 
between the groups (Table 1). 









































Counts and percentages of CD4+ and CD8+ T-cells 
 
We first identified CD4+ and CD8+ T-cells (Figure 1). 
Groups did not differ significantly in CD4+ and CD8+ 
T-cells counts and percentages. Patients with PCV had a 
mean CD4+ T-cell count of 846 (SD: 414) cells/mm3 
constituting 43 (SD: 13) % of total lymphocytes, not 
significantly different from that in patients with 
neovascular AMD (count: mean 754 (SD: 334) 
cells/mm3; percentage: mean 45 (SD: 12) %) or healthy 
controls (count: mean 796 (SD: 204) cells/mm3, 
percentage: 48 (SD: 9) %) (P = 0.55 and P = 0.37, for 
count and percentage respectively, using one-way 
analysis of variance).  Patients with PCV had a mean 
CD8+ T-cell count of 581 (SD: 224) cells/mm3 









































not significantly different from that in patients with 
neovascular AMD (count: mean 499 (SD: 197) 
cells/mm3; percentage: mean 31 (SD: 10) %) or healthy 
controls (count: mean 504 (SD: 261) cells/mm3, 
percentage: 29 (SD: 10) %) (P = 0.32 and P = 0.73, for 
count and percentage respectively, using one-way 
analysis of variance). 
 
Differentiation profile of CD4+ and CD8+ T-cells 
 
The functional differentiation profile (naïve T-cells, 
central memory T-cells, effector memory T-cells, 
effector memory CD45ra+ T-cells) in CD4+ and CD8+ 
T-cells did not differ significantly between patients with 
PCV, patients with neovascular AMD, and healthy 













     
Demographics     
Age, years, mean (SD) 72.5 (7.9) 75.8 (7.3) 73.4 (7.7) 0.20 a 
Females, n, (%) 15 (63) 23 (51) 15 (63) 0.54 b 
     
Co-morbidities     
Hypertension, n (%) 9 (38) 23 (51) 7 (29) 0.19 b 
Cardiovascular disease, n 
(%) 
4 (17) 10 (22) 2 (8) 0.38 c 
Hypercholesterolemia, n (%) 7 (29) 10 (22) 6 (25) 0.82 b 
Type 2 diabetes, n (%) 2 (8) 6 (13) 0 (0) 0.17 c 
     
Lifestyle factors     
Smoking, n (%)    0.091 c 
    Current 8 (33) 14 (31) 3 (12)  
    Previous 13 (54) 18 (40) 10 (42)  
    Never 3 (13) 13 (29) 11 (46)  
Alcohol consumption, units, 
median (IQR) 
4 (1 to 12) 3 (1 to 9) 4 (2 to 7) 0.67 d 
Body mass index, mean (SD) 24.4 (3.4) 26.2 (4.0) 25.7 (3.1) 0.16 a 
Physically active, n (%) 13 (54) 23 (51) 17 (71) 0.27 b 
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Wallis test) (Figure 2). We found no significant 
differences between groups in memory to naïve T-cell 





















































in CD8+ T-cells (P = 0.15, Kruskal-Wallis test). 
Memory to naïve T-cell ratio in CD4+ T-cells was not 






















































leukocytes  were  identified  using  forward  scatter  height  vs.  area  scatter  on  a  combined  contour  and  density  plot.  (B)
Lymphocytes were identified using forward scatter area vs. side scatter area on a combined contour and density plot. (C) CD4+
and CD4‐  lymphocytes were  identified with the help of negative  isotype controls (set at 1% to distinguish fluorescence signal
from  non‐specific  background  signals).  (D)  CD4+  and  CD4‐  lymphocytes were  identified with  the  help  of  negative  isotype
controls  (set at 1% to distinguish fluorescence signal from non‐specific background signals). Using  logical Boolean sequences,
we distinguished two T‐cell populations for further analyses: CD4+ T‐cells that were CD4+CD8‐ and CD8+ T‐cells that were CD4‐CD8+.
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neovascular AMD, or in healthy controls; however, in 
CD8+ T-cells we observed a weak correlation in patients 




















































healthy controls (ρ = +0.3, Spearman’s correlation), 
which was stronger in patients with neovascular AMD 






















































Figure 2.  Functional  differentiation  profile  of  CD4+  and  CD8+  T‐cells  in  patients with  polypoidal  choroidal  vasculopathy  (PCV),
patients with  neovascular  age‐related macular  degeneration  (nAMD),  and  healthy  controls.  Cells were  defined  as  naïve  T‐cells
CD45ra+CD45ro‐CCR7+,  central memory  T‐cells  (CM)  CD45ra‐CD45ro+CCR7+,  effector memory  T‐cells  (EM)  CD45ra‐CD45ro+CCR7‐,































Loss of CD27 and CD28 expression in CD4+ and 
CD8+ T-cells 
 
Loss of CD27 and CD28 expression in T-cells were 
correlated to the functional differentiation profile as 
expected (Table 2). Differences in T-cell differentiation 
between groups were observed when comparing loss of 
CD27 and CD28. Loss of CD27 and CD28 expression 
in CD4+ T-cells did not differ patients with PCV and 
patients with neovascular AMD and were comparable to 
healthy controls (Figure 3). Increasing age was weakly 
correlated with loss of CD27 expression in CD4+ T-
cells and not subject to group differences (Figure 3). In 
patients with neovascular AMD, we observed that loss 
of CD27 in CD8+ CD28- T-cells was significantly 
increased compared to healthy controls (P = 0.019, 
Mann-Whitney U-test), whereas no significant 
differences were observed between patients with PCV 
and healthy controls (P = 0.56, Mann-Whitney U-test) 
(Figure 3). Loss of CD28 and CD27 in CD8+ T-cells 
were moderately correlated with age in patients with 
PCV (CD28- : ρ = +0.6, Spearman’s correlation; CD27- 
: ρ = +0.4, Spearman’s correlation), patients with neo-
vascular AMD (CD28- : ρ = +0.5, Spearman’s 
correlation; CD27- : ρ = +0.5, Spearman’s correlation), 
and in healthy controls (CD28- : ρ = +0.4, Spearman’s 
correlation; CD27- : ρ = +0.4, Spearman’s correlation). 
Similar results were observed in CD8+CD28-CD27- but 




























Percentage of CD56+ cells in CD4+ and CD8+ T-cells 
 
Patients with PCV did not differ from patients with 
neovascular AMD in CD56+ cells in CD4+ T-cells, and 
both patient groups had levels similar to that in healthy 
controls (Figure 4). However, while CD56+ in CD8+ T-
cells were comparable between patients with PCV and 
healthy controls, it was significantly increased in 
patients with neovascular AMD (Figure 4). Aging 
correlated moderately with CD56 surface expression in 
CD8+ T-cells in patients with PCV (ρ = +0.4, 
Spearman’s correlation) and in healthy controls (ρ = 
+0.5, Spearman’s correlation). In patients with neo-
vascular AMD, we observed an inverse correlation 
between age and CD56+ CD8+ T-cells (ρ = -0.3, 
Spearman’s correlation) (Figure 5). Because of this 
finding and to further investigate aging and CD56+ cells 
in CD8+ T-cells, we stratified all participants on age and 
repeated the comparisons across groups of diagnosis 
(Table 3). Patients with PCV and patients with 
neovascular AMD had levels comparable to healthy 
controls among those aged >70 and ≤80 years and those 
aged >80 years. However, among the younger 
participants (aged ≤70 years), patients with neovascular 
AMD had significantly higher CD56+ expression in 
CD8+ T-cells than patients with PCV (P = 3.2 × 10-4, 
Mann-Whitney U test) or healthy controls (P = 9.1 × 10-5, 
Mann-Whitney U test) (Table 3). 
 
Table  2.  Loss  of  CD27  and  CD28  expression  on  CD4+  and  CD8+  T‐cells  subsets  of  functional 
differentiation. 
 Naïve CM EM EMRA 
     
CD4+ T-cells     
% CD27-, median (IQR) 0 (0 to 0) 1 (1 to 2) 21 (13 to 29) 12 (5 to 46) 
% CD28-, median (IQR) 0 (0 to 0) 0 (0 to 0) 2 (0 to 9) 8 (2 to 37) 
% CD28- in CD27- cells, median 
(IQR) 
Very few cells Very few cells 10 (1 to 36) 64 (17 to 87) 
     
CD8+ T-cells     
% CD28-, median (IQR) 5 (2 to 12) 1 (0 to 2) 24 (11 to 42) 92 (88 to 95) 
% CD27-, median (IQR) 3 (1 to 7) 2 (1 to 4) 18 (11 to 29) 80 (72 to 87) 
% CD27- in CD28- cells, median 
(IQR) 




later, whereas  the  opposite  is  the  case  for  CD8+  T‐cells which  lose  CD28  first  and  CD27  later.  These 
changes are also reflected when looked in CD4+ and CD8+ T‐cell subsets of functional differentiation. 

















































































































Figure  3.  T‐cell  differentiation measured  as  CD27  and  CD28  downregulation  in  patients with  polypoidal  choroidal  vasculopathy




proportion compared  to  the other groups.  (D) Age‐related changes  in CD27 and CD28  loss were comparable between  the groups.
CD4+CD28‐ and CD4+CD27‐CD28‐ were not included due to numbers close to the extremes yielding unstable correlation analyses.  




















































































































 Patients with PCV 
(n = 24) 
Patients with nAMD
(n = 45) 
Healthy controls 
(n = 24) 
P-value 
     
Aged ≤70 years (n = 10) (n = 11) (n = 8)  
% CD56+, median (IQR) 75 (72 to 78) 91 (87 to 93) 74 (70 to 80) 0.00030 
     
Aged >70 and ≤80 years (n = 10) (n = 23) (n = 11)  
% CD56+, median (IQR) 83 (78 to 86) 86 (79 to 91) 83 (80 to 87) 0.48 
     
Aged >80 years (n = 4) (n = 13) (n = 5)  
% CD56+, median (IQR) 81 (76 to 85) 84 (76 to 90) 84 (84 to 86) 0.86 
Abbreviations:  PCV  =  polypoidal  choroidal  vasculopathy;  nAMD  =  neovascular  age‐related  macular 
degeneration; IQR = interquartile range. 





 Patients with PCV 
(n = 24) 
Patients with nAMD 
(n = 45) 
Healthy controls 
(n = 24) 
P-value 
     
CD4+ T-cells     
% Naïve CD56+, median (IQR) 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) 0.55 
% CM CD56+, median (IQR) 0 (0 to 1) 1 (0 to 2) 1 (0 to 2) 0.20 
% EM CD56+, median (IQR) 0 (0 to 1) 0 (0 to 1) 1 (0 to 1) 0.28 
% EMRA CD56+, median (IQR) 2 (0 to 19) 1 (0 to 10) 1 (0 to 6) 0.43 
     
CD8+ T-cells     
% Naïve CD56+, median (IQR) 92 (82 to 96) 95 (90 to 97) 94 (88 to 96) 0.11 
% CM CD56+, median (IQR) 92 (87 to 96) 96 (94 to 98) 95 (89 to 98) 0.027 
% EM CD56+, median (IQR) 88 (81 to 94) 93 (89 to 96) 88 (83 to 91) 0.011 
% EMRA CD56+, median (IQR) 70 (64 to 81) 79 (67 to 88) 75 (62 to 81) 0.092 
Abbreviations: PCV = polypoidal choroidal vasculopathy; nAMD = neovascular age‐related macular degeneration; 
IQR = interquartile range; CM = central memory; EM = effector memory; EMRA = effector memory CD45ra+. 
Naïve  T‐cells  are  CD45ra+CD45ro‐CCR7+,  CM  T‐cells  are  CD45ra‐CD45ro+CCR7+,  EM  T‐cells  are  CD45ra‐
CD45ro+CCR7‐, and EMRA T‐cells are CD45ra+CD45ro+CCR7‐. 
Statistical comparisons are made using Kruskal‐Wallis’ test. Bold text indicates a statistically significant difference. 









































Percentage of CD56+ cells by CD4+ and CD8+ T-cell 
differentiation level 
 
We did not find any differences in CD56+ cells in any 
functional differentiation subset of CD4+ T-cells (Table 
4). CD56 expression in Naïve and EMRA CD8+ T-cells 
also did not differ between the groups (P = 0.11 and P = 
0.092, for Naïve and EMRA CD8+ T-cells, respectively, 
using Kruskal-Wallis test) (Table 4). Patients with 
neovascular AMD has significantly more CD56+ in EM 
cells compared to healthy controls (P = 0.0065, Mann-
Whitney U test), whereas CM was not significantly 
different between the two groups (P = 0.23, Mann-
Whitney U test). Patients with neovascular AMD had 
significantly more CD56+ in both CM (P = 0.0063, 









































Whitney U test) when compared to patients with PCV. 
CD56+ in CM and EM in CD8+ T-cells did not differ 
significantly between patients with PCV and healthy 
controls (P = 0.28 and P = 0.77, for CM and EM, 
respectively, using Mann-Whitney U test). 
 
CD56+ in CD27- and CD28- cells did not differ 
significantly between groups in CD4+ T-cells (Table 5). 
In CD8+ T-cells, significantly more CD56+ was 
observed in CD28-, CD27-, and CD28-CD27- subsets in 
patients with neovascular AMD when compared to 
patients with PCV (P = 0.0028, P = 0.022, P = 0.0070, 
CD28-, CD27-, and CD28-CD27- respectively, using 
Mann-Whitney U test) or healthy controls (P = 0.048, P 
= 0.044, P = 0.062, CD28-, CD27-, and CD28-CD27- 
respectively, using Mann-Whitney U test) (Table 5). 
Figure 4. Proportion of CD56+ CD4+ and CD8+ T‐cells in patients with polypoidal choroidal vasculopathy (PCV), patients
with  neovascular  age‐related  macular  degeneration  (nAMD),  and  healthy  controls.  (A)  CD56+  CD4+  T‐cells  were
identified with  the  help  of  negative  isotype  controls  (set  at  1%  to  distinguish  fluorescence  signal  from  non‐specific
background signals). (B) CD56+ in CD4+ T‐cells did not differ between the groups. Horizontal line with whiskers indicate
median and interquartile range. (C) CD56+ CD8+ T‐cells were identified with the help of negative isotype controls (set at
1%  to  distinguish  fluorescence  signal  from  non‐specific  background  signals).  (D)  CD56+  in  CD8+  T‐cells  differed
significantly and was significantly higher in patients with nAMD (signified with *, P = 0.0016, Kruskal‐Wallis test).  
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CD56+ in CD28- (P = 0.67, Mann-Whitney U test), 
CD27- (P = 0.21, Mann-Whitney U test), and CD28-
CD27- (P = 0.33, Mann-Whitney U test) did not differ 

























Are PCV and neovascular AMD etiologically similar or 
























terms of systemic T-cell profile of differentiation and 
aging. Patients with PCV were similar to healthy 
controls in all aspects of T-cells differentiation and 
percentage of CD56+ T-cells. In contrast, we found 
multiple sources of evidence suggesting a more accele-
rated differentiation and aging profile in patients with 
neovascular AMD. Ample evidence links an aging 
immune system to the presence of nonspecific inflam-
mation, which accelerate development of age-related 
degenerative diseases. Our findings are in line with the 
general conception of neovascular AMD as a degene-
rative disease of the macula and within that framework, 
immunosenescence as a contributing or an accompany-
ing factor may not come as a surprise. Neurodegene-
ration and inflammation lead to drusen formation in 
AMD which precedes formation of the new choroidal 
vessels that defines neovascular AMD. The lack of an 
association with drusen formation in PCV have so far 
raised the question of whether or not AMD and PCV 
may differ etiologically [34]. Based on our findings in 
this study, we suggest that PCV should be considered 
etiologically different from neovascular AMD, at least 
in terms of T-cell differentiation and aging.  
 
The T-cell pool in elderly humans are maintained by 
proliferation of the existing naïve T-cells [35,36]. Naïve 
T-cells are eventually spent due to antigen exposure and 
differentiate into CM, and eventually into EM and 
EMRA, also known as terminal effector memory cells. 
Näive T-cells are characterized as being highly 
proliferative and lightly cytotoxic T-cells in contrast to 




























 Patients with PCV
(n = 24) 
Patients with nAMD
(n = 45) 
Healthy controls 
(n = 24) 
P-value 
     
CD4+ T-cells     
% CD27-CD56+, median (IQR) 3 (1 to 12) 3 (1 to 12) 2 (1 to 10) 0.93 
% CD28-CD56+, median (IQR) 7 (1 to 28) 4 (0 to 22) 7 (0 to 24) 0.94 
% CD27-CD28-CD56+, median (IQR) 7 (0 to 27) 8 (0 to 32) 10 (0 to 27) 0.97 
     
CD8+ T-cells     
% CD28-CD56+, median (IQR) 73 (64 to 81) 84 (69 to 88) 76 (63 to 83) 0.030 
% CD27-CD56+, median (IQR) 72 (60 to 81) 84 (72 to 88) 79 (65 to 83) 0.0057 





Figure  5.  Age‐related  changes  in  %  of  CD56+  CD8+  T‐cells  in
patients with polypoidal choroidal vasculopathy  (PCV), patients
with  neovascular  age‐related  macular  degeneration  (nAMD),
and healthy controls. 
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cytotoxic [37]. Previous studies on aging and T-cells 
have demonstrated that in numbers, naïve CD4+ T-cells 
remain relatively stable with age [36,38], whereas naïve 
CD8+ T-cells undergo a substantial age-related 
decrement [36,38,39]. This is in line with our findings 
where the memory-to-naïve T-cell ratio remained 
relatively unchanged with age in CD4+ T-cells and 
increased with age in CD8+ T-cells. This increase was 
stronger in patients with neovascular AMD than in 
patients with PCV and healthy controls, but we did not 
find statistical significant differences when distributions 
of differentiation subsets were compared. Interestingly, 
Ezzat et al. studied human choroid from donor eyes 
using immunohistochemistry and found that CD8+ cells 
were abundantly present in maculae with AMD [40]. 
The picture is less clear for PCV. In surgically excised 
specimens of PCV, Lafaut et al. confirmed presence of 
aneurysmal vessel dilations but also found islands of 
possible lymphocytic infiltration [41]. Nakashizuka et 
al. identified immune cells around the abnormal vessels 
to be foamy-macrophages; however, the authors did not 
specifically investigate T-cells or lymphocytes immuno-
histochemically [42]. Okubo et al. identified occasional 
extravascular located macrophages posterior to the 
dilated vessels, but reported no presence of lymphocytes 
[43]. 
 
CD27 and CD28 on T-cells interact with molecules 
presented by the antigen presenting cells [37]. 
Proliferation and differentiation leads to loss of CD27 
and CD28: naïve T-cells are CD27++ and CD28++, CM 
are CD27++ and CD28++, EM are CD27+/- and CD28+/-, 
and EMRA are CD27- and CD28- [37]. These changes 
differ slightly between CD4+ and CD8+ T-cell 
populations: in CD4+ T-cells, proliferation and 
differentiation leads first to CD27- and then CD28- later 
whereas the opposite is the case in CD8+ T-cells with 
first CD28- and then CD27- [31]. These characteristics 
are in line with the findings in this study (Table 2). An 
age-related increase in CD27- and CD28- T-cells are 
well-characterized in human aging [37]. Accelerated 
loss of CD28 expression, and to some degree also loss 
of CD27 expression, have also been linked to 
stimulation with the common cytokine gamma-chain 
family (interleukin(IL)-2, IL-4, IL-7, IL-9, IL-15, and 
IL-21) [44,45]. Some of these cytokines have been 
investigated in patients with PCV and patients with 
neovascular AMD, in particular IL-4 is found to be 
increased in both PCV and neovascular AMD [46]. 
Despite these previous findings, we only found that 
patients with neovascular AMD, and not patients with 
PCV, had a significantly more CD27- and CD28- and 
exclusively as CD8+CD28-CD27- T-cells. This does not 
exclude a possible role for IL-4 in PCV, but our results 
suggest that CD28-CD27- T-cells have less significant 
role in PCV than in neovascular AMD. Our data is the 
first to suggest that CD8+CD28-CD27- T-cells may play 
a role in neovascular AMD. CD8+CD28-CD27- T-cells 
are terminally differentiated, have limited capacity of 
proliferation and survival due to shortened telomeres, 
and are highly cytotoxic [44]. Interestingly, CD8+CD28- 
T-cells are suspected to reflect exhaustion of the 
adaptive immune system and it is hypothesized that 
their accumulation with age contribute to age-related 
diseases by counteracting the impact of protective T-
cells [44]. An acceleration of this process is seen in 
individuals with cytomegalovirus infection [47,48], 
which is particularly relevant for AMD since prior 
cytomegalovirus infection measured as specific IgG 
titer is demonstrated to be significantly associated with 
later development of neovascular AMD [49]. 
 
CD56+ T-cells are an interesting subtype with cytokine-
induced cytolytic abilities similar to natural killer cells, 
but without the natural killer cell-associated receptors of 
activation or inhibition [50]. Through increased p16 
expression, which directly inhibits cellular mitosis, 
CD56+ T-cells have limited ability of proliferation [33]. 
Proportion of CD56+ T-cells increase with age and its 
expression has been suggested as a marker of 
immunological aging [33]. CD56+ in CD4+ T-cells are 
generally low and its expression is usually much more 
abundant in CD8+ T-cells [33,50]. Exact function of 
CD56 on T-cells and its possible ligands remains 
incompletely characterized, but one study identified 
fibroblast growth factor receptor 1 (FGFR-1) as a ligand 
for CD56 [51]. FGFR-1 is expressed in human macular 
specimens of neovascular AMD and experimental 
studies find increased FGFR-1 expression upon retinal 
injury from the photoreceptors and the RPE, and FGFR-
1 expression itself enhances the expression of VEGF 
[52,53]. In mice, Oladipupo et al. found that endothelial 
FGFR-1 is essential for neovascularization following 
retinal injury [54]. Lemster et al. mapped the production 
of cytokines in CD56+ T-cells upon in vitro CD56 
ligation using CD56-specific antibodies [33] and found 
secretion of interferon gamma (IFN-γ), IL-2, IL-8, IL-
13, monocyte chemoattractant protein-1 (MCP-1), 
macrophage inflammatory protein 1 beta (MIP-1β), and 
tumor necrosis factor alpha (TNF-α). These circum-
stances are interesting in light of the striking differences 
in the proportion of T-cells that are CD8+CD56+: 
patients with PCV did not differ from healthy control 
individuals, but patients with neovascular AMD had 
significantly higher proportion of CD8+CD56+ T-cells. 
Higher proportion of CD56+ T-cells in patients with 
neovascular AMD were not seen as unspecific general 
increase in the proportion of CD56+ cells, but 
specifically in the CD8+ CM and EM populations which 
are highly cytotoxic. Considering that neovascular 
AMD, unlike PCV, is preceded by development of 
drusen, retinal injury, and RPE dysfunction, an 
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accelerated immunological aging that leads to increased 
CD56+ T-cells may function synergistically to recruit 
systemic monocytes, activate macrophages, and shape a 
predominantly pro-inflammatory environment that 
propel a residential angiogenic drive, expression of 
VEGF, and consequently development of neovascular 
AMD. Supporting these hypotheses are the facts that 
both increased CD56 expression on T-cells and CD8+ 
memory-to-naïve T-cell ratio have been linked to 
accelerated aging [31-33,36,38,39], as well as obser-
vational studies in patients with AMD and experimental 
studies in mice of laser-induced CNV, where data 
suggest significant contribution of systemic and local 
concentrations of IFN-γ, IL-8, IL-13, MCP-1, MIP-1β, 
and TNF-α [55]. The link between increased CD56+ T-
cells and neovascular AMD is independent of important 
risk factors for neovascular AMD that likely could 
influence our results, such as cytomegalovirus sero-
positivity and smoking as investigated by our group in a 
previous study [11]. 
 
We made another very interesting observation in 
proportion of CD56+ CD8+ T-cells by investigating 
age-related changes: the significantly higher CD56+ was 
exclusive to the younger group of patients with 
neovascular AMD (P = 0.00016). Approximately 30 % 
of individuals above the age of 60 have drusen [56], but 
only approx. 5 % in 5 years and 15 % in 15 years 
develop later stages of the disease [3]. Many individuals 
with early AMD never develop late AMD, but age is the 
single greatest risk of developing late AMD including 
neovascular AMD [1]. Hence, younger (≤ 70 years) 
patients with neovascular AMD constitute an etiolo-
gically interesting group. Differences in immunological 
aging may explain why some relatively young patients 
with AMD progress to the neovascular subtype of 
AMD. Results of this study suggest that immunological 
focus is warranted on young patients with neovascular 
AMD. 
 
It is important to acknowledge limitations of our study 
design, which enable correlations with disease but not 
infer on causality. In addition, we are unable to 
distinguish whether observed changes preceded 
development of disease or reflect a systemic adaptation 
of retinal injury. Possible causation should be invest-
tigated in future studies using experimental methods. 
 
In conclusion, we find differences between patients with 
PCV and patients with neovascular AMD in CD8+ T-
cells, particularly in the proportion of CD28-CD27- cells 
and CD56+ cells. Our data suggest that PCV is similar 
to healthy controls in terms of T-cell differentiation and 
aging, and that neovascular AMD is a disease wherein 
these aspects may be accelerated. Considering that 
aging is the strongest predictor of neovascular AMD 
and the findings in this study revealing that younger 
patients with neovascular AMD have higher CD56+ in 
CD8+ T-cells, we propose that younger patients with 
neovascular AMD may constitute an interesting 




This study was approved by the Regional Committee of 
Ethics in Research of the Region of Zealand (SJ-379) 
and followed the principles of ethics in human research 
as stated in the Declaration of Helsinki. We explained 
the nature of the study to all participants and obtained 




We recruited patients from the Department of 
Ophthalmology at Zealand University Hospital 
Roskilde for this prospective case-control study. 
Participants were either patients with PCV, patients 
with neovascular AMD, or age-matched (aged ≥ 60 
years) healthy controls. Healthy controls were recruited 
from healthy biologically unrelated relatives of 
recruited patients (e.g. husband or wife) to better match 
the control group in terms of environmental exposures. 
A direct power calculation for this study was not 
possible since very few studies have investigated 
systemic components of PCV and no studies of patients 
with PCV have described their T-cell differentiation 
profile or expression of aging marker CD56. However, 
we have previously investigated CD28-CD56+ CD8+ T-
cells in patients with neovascular AMD [11], and based 
on these experiences we approximated that at least 16 
participants would be necessary to study CD56 in CD8+ 
T-cells (assuming an alpha level of 5 %, power level of 
80%, means of ~18 % and ~28 % in controls and 
patients respectively, and a standard deviation of ~10 
%). To ensure sufficient power in this study of patients 
with PCV, we recruited at least 20 in each group and 





All participants underwent comprehensive ocular 
examination using slit-lamp bio-microscopy, digital 
fundus photography, and Spectral Domain Optical 
Coherence Tomography (SD-OCT). Best-corrected 
visual acuity (BCVA) was measured in each eye using 
the Early Treatment of Diabetic Retinopathy Study 
(ETDRS) chart [57]. Using the Clinical Age-Related 
Maculopathy Staging (CARMS) definition [58], healthy 
controls were defined as having less than 10 small 
drusen (<63 μm) in both eyes with no sign of pigment 
abnormalities. Fluorescein and indocyanine green 
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angiography (ICGA) was used for macular diagnostics 
to classify the disease into neovascular AMD or PCV 
[13]. Neovascular AMD was diagnosed in cases with 
fibrovascular RPE detachments and choroidal 
neovascular membranes with subretinal or sub-RPE 
hemorrhages or fibrosis [35], in addition to the presence 
of drusen. PCV was diagnosed in cases with one or 
more polyps seen in the early-phase ICGA with a 
hypofluorescent halo and with or without BVN [12-14].  
 
Inclusion and exclusion criteria of participants 
 
We included participants with either PCV in one or both 
eyes, neovascular AMD in one or both eyes, or healthy 
retinas. Participants were only included if they had no 
history of an ongoing immune disease (e.g. any 
diagnose of cancer, autoimmune diseases, or infectious 
diseases) or immune modulating treatment (i.e. 
chemotherapy, immune therapy, steroids, or any other 
therapy with the purpose of modulating immune 
function) to avoid blurring of results. Participants were 
only included if they had not received VEGF inhibitors 
within 4 weeks (Ranibizumab, Novartis, Basel, 
Switzerland) or 8 weeks (Aflibercept, Bayer, Lever-
kusen, Germany) to avoid potential interaction of 
systemic antibodies in flow cytometric preparations. 
Detailed diagnosis with retinal angiography was made 
on treatment-naïve eyes, but patients were not recruited 
on their initial visit because recent onset of CNV is 
associated with acute immune activity [6]. We 
measured plasma C-reactive protein and post-hoc 
excluded any participant with levels >15 mg·L-1 to 
avoid including participants with an ongoing 
immunological acute response [59]. 
 
Clinical data  
 
All participants were interviewed for co-morbidities and 
treatments, and we crosschecked the data with the 
patient’s electronic patient record. Smoking was noted 
as current, previous (>100 cigarettes in total, but ceased 
smoking >12 months), or never smokers. Alcohol use 
was noted in units/week (one Danish unit = 15 mL or 12 
g  pure  ethanol).   General   state   of  physical  activity/ 
inactivity was noted using a single question for 
epidemiological studies [60,61]. Body mass index 
(BMI) was calculated using height and weight. 
 
Blood sampling and preparation for flow cytometry 
 
We sampled venous blood in one tube coated with 
lithium heparin to measure C-reactive protein and one 
tube coated with ethylenediaminetetraacetic acid 
(EDTA). The EDTA stabilized blood was prepared for 
flow cytometric analysis within 4 hours of blood 
sampling. We obtained a differential count using the 
automated hematology analyzed Sysmex KX-21NTM 
(Sysmex Corporation, Kobe, Japan) and the white blood 
cell count was used to calculate blood volume needed to 
obtain a constant final number leukocytes in the test 
tubes (5·105 leukocytes). Sampled blood underwent 
erythrocyte lysis using red blood cell lysis buffer 
(Nordic Biosite AB, Täby, Sweden) in dark at room 
temperature for 10 minutes. We then washed cells three 
times by centrifuging (5 minutes at 500 G) and re-
suspending in an isotonic buffer solution (BD 
FACSFlowTM, BD Biosciences, Franklin Lakes, NJ, 
USA). We incubated the cells in dark at room 
temperature for 20 minutes after adding target-specific 
monoclonal fluorescent antibodies to the test tube (CD4 
(Peridinin-chlorophyll protein complex, IgG2a, 
FAB3791C-100, R&D Systems Inc., Minneapolis, MN, 
USA), CD8 (Phycoerythrin-CY7, IgG1, 300914, 
BioLegend, San Diego, CA, USA), CD45ra (Pacific 
Blue, IgG2b, 304123, BioLegend), CD45ro 
(Fluorescein Isothiocyanate, IgG2a, MCA461, Bio-Rad 
Laboratories Inc., Hercules, CA, USA), CCR7 (Brilliant 
Violet 510, IgG2a, 353232, BioLegend), CD27 
(Phycoerythrin, IgG1, 356406, BioLegend), CD28 
(Allophycocyanine, IgG1, 301912, BioLegend), and 
CD56 (Allophycocyanine-CY7, IgG1, 318332, 
BioLegend)) and flourochrome-matched negative 
isotypes to a separate tube (Peridinin-chlorophyll 
protein complex, IgG2a (400250, BioLegend); 
Phycoerythrin-CY7, IgG1 (400126, BioLegend); Pacific 
Blue, IgG2b (400331, BioLegend); Fluorescein 
Isothiocyanate, IgG2a (MCA461, Bio-Rad Laboratories 
Inc.); Brilliant Violet 510, IgG2a (400172, BioLegend); 
Phycoerythrin, IgG1 (555749, BD Biosciences); 
Allophycocyanine, IgG1 (400120, BioLegend); 
Allophycocyanine-CY7, IgG1 (400128, BioLegend)). 
After incubation, cells were washed and analyzed using 
flow cytometry (BD FACSCanto IITM, BD Biosciences, 
Franklin Lakes, NJ, USA) with a sample size of 
100.000 singlet leukocytes using a pre-set gate.  
 
Analysis of flow cytometric data 
 
All flow cytometric data were analyzed using Kaluza 
Analysis software (Kaluza Analysis v. 1.5.20365.16139, 
Beckman Coulter Inc., Pasadena, CA, USA) by two 
independent evaluators (authors Y.S. and M.K.N.) in a 
blinded fashion to the participants’ condition. We 
obtained T-cell specific results by using following 
gating strategy: 1) singlet leukocytes (using forward 
scatter area vs. height), 2) lymphocytes (using forward 
scatter area vs. side scatter area), 3) CD4+CD8- (CD4+ 
T-cells) or CD4-CD8+ (CD8+ T-cells) (using the 
fluorescence of target-specific antibodies for CD4 vs. 
CD8). Identification of T-cells are illustrated in Figure 
1. Percentages of CD4+ and CD8+ T-cells in the 
lymphocyte population were combined with differential 
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count numbers obtained from the automated 
hematology analyzer to obtain CD4+ and CD8+ T-cell 
counts in cells/mm3. Functional differentiation profile 
was defined as naïve T-cells CD45ra+CD45ro-CCR7+, 
central memory T-cells CD45ra-CD45ro+CCR7+ (CM), 
effector memory T-cells CD45ra-CD45ro+ [62]. The 
distribution of these subsets were investigated in CD4+ 
and CD8+ T-cells separately. In CD4+ T-cells, we 
determined % CD27-, % CD28-, and % CD28- in CD27- 
cells. In CD8+ T-cells, we determined % CD28-, % 
CD27-, and % CD27- in CD28- cells. We determined 
expression of CD56 as % positive in CD4+ and CD8+ T-
cells and in their differentiation subsets using logical 
Boolean sequences in Kaluza Analysis software. When 
positive cell populations were not clearly distin-
guishable from negative cell populations due to non-
specific signaling, the non-specific signaling were 
eliminated by gating the corresponding negative isotype 




Statistics were performed using SPSS 23 (IBM 
Corporation, Armonk, NY, USA). Normally distributed 
continuous data were presented in mean and standard 
deviation (SD) and compared using parametric tests; 
otherwise data were presented in median and inter-
quartile range (IQR) and compared using non-
parametric tests. Categorical variables were presented in 
numbers and percentages and tested using χ2 test or we 
used the Fisher’s Exact test when dealing with small 
categories (n<5). Correlations with age were made 
using Spearman’s ranked correlation due to lack of 
normal distribution. When dealing with proportion 
variables where data were in the extremes (very low or 
very high), we avoided correlations as such analyses 
would be extremely prone to outliers and yield unstable 
results. Figures were made with Prism 7 software 
(GraphPad, La Jolla, CA, USA). P-values below 0.05 
were interpret as sign of statistical significance. 
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